AUTHORS
Amanda Waller, PhD, MSc, Kaushik Muralidharan, Postdoctoral Scientist2, Katelyn Wolfgang3, Mayra Oseguera4, Eman Abdelghani, MD5, Brittney Spruill6, Iva Pruner, PhD7, Bryce Kerlin, MD8
AFFILIATIONS
1 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
2 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
3 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
4 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
5 Innovative Hematology and the Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States
6 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
7 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
8 The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
ABSTRACT
Background: Podocyte injury is a key determinant of chronic kidney disease (CKD) progression toward end stage kidney disease. We and others have recently uncovered a putative podocytopathic role for intraglomerular thrombin during proteinuric glomerular disease. We previously demonstrated in rat models of acute glomerular disease that (pro)thrombin (F2) knockdown and both direct (dabigatran) and indirect (rivaroxaban) FII antagonism improved podocyte injury, disease activity, and progression. However, the mechanisms behind intraglomerular thrombin generation during proteinuria remain unknown. This study aimed to determine if factor X (F10) knockdown would mirror the effects of F2 knockdown during proteinuria. We hypothesized that genetic knockdown of either F2 or F10 would improve kidney function in a murine model of progressive glomerular disease.
Methods: F2- and F10- knockdown mice (F2lox/- and F10Friuli/Friuli, respectively) were crossed with podocin-Cre; inducible diphtheria toxin receptor mice and compared to wild-type (WT) mice with normal F2 and F10 loci (N=12-16/group). On Day 0, podocyte-specific proteinuria was induced by a single intraperitoneal injection of 1 ng/g diphtheria toxin (DT) and compared to healthy (no DT) controls. In a follow-up experiment, WT and F10 deficient mice with DT-induced proteinuria were treated with rivaroxaban administered in the normal chow at 0.4 mg/g from days 5-35.
Spot urine samples were collected every 4-7 days for albumin:creatinine measurement. Transcutaneous FITC-sinistrin Glomerular Filtration Rate (GFR) was measured at baseline and day 34. The study ended with collection of tissues and citrated whole blood on day 35. Glomeruli were isolated by magnetic beads, dissociated into single-cell suspensions, and analyzed by flow cytometry after immunofluorescent antibody and TUNEL staining. Plasma FII and FX activities were measured by chromogenic assay.
Results: Prothrombin and factor X activities were 9.7% ± 2.63 and 15.9% ± 7.54 of WT levels in the F2lox/- and F10Friuli/Friuli mice, respectively (P<0.001). Compared to WT mice, albuminuria was decreased in F2lox/- mice from day 9 through 35 (27.5% ± 3.62 average decrease vs WT; P<0.01). In contrast, albuminuria in the F10Friuli/Friuli mice was not significantly different from WT (10.2% ± 3.51 decrease vs WT over the same period; P=0.250). By day 34, GFR in the WT mice was 34.2% ± 1.88 lower than healthy control mice (1.44 ± 0.08 vs 2.19 ± 0.17 mL/min/100g body weight in the WT vs control mice, respectively; P=0.043). Prothrombin knockdown improved day 34 GFR, resulting in a 29.3% ± 2.68 increase in the F2lox/- mice (2.04 ± 0.19 mL/min/100 g body weight; P = 0.010 vs. WT). In contrast, day 34 GFR in the F10Friuli/Friuli mice was 1.67 ± 0.16 mL/min/100g body weight; a 13.6% ± 1.32 improvement over WT levels (P=0.224; NS). Prothrombin knockdown also reduced in situ podocyte injury at day 35, such that the proportion of TUNEL-positive podocytes was 26.4% ±1.61 decreased in the F2lox/- mice compared to WT mice (P<0.042), whereas F10Friuli/Friuli mice were 9.7% ±1.78 decreased (P=0.104; NS). In the second study, the therapeutic dosage of rivaroxaban averaged 0.056 ± 0.006 mg/g body weight per day. Rivaroxaban treatment significantly decreased podocyte injury, improved GFR and ameliorated proteinuria in both WT and F10Friuli/Friuli mice (P<0.05).
Discussion: Genetic knockdown of prothrombin, but not factor X, reduced albuminuria, alleviated podocytopathy, and improved glomerular function in a mouse model of progressive glomerular disease. Intriguingly, rivaroxaban treatment of factor X deficient mice significantly improved disease severity in this model, suggesting potential inhibition through an alternative, rivaroxaban sensitive prothrombinase. These results further support that thrombin plays a central role in proteinuric glomerular disease progression; however, the mechanism by which thrombin is produced within the glomerulus remains unknown.
DISCLOSURES
Amanda Waller, PhD, MSc: No relevant conflicts of interest to declare.